Alpa Laboratories [ALPA] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison
Alpa Laboratories
NSE
Loading...
Sun Pharmaceutical
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Alpa Laboratories wins in 7 metrics, Sun Pharmaceutical wins in 11 metrics, with 0 ties. Sun Pharmaceutical appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Alpa Laboratories | Sun Pharmaceutical | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 7.55 | 37.28 | Alpa Laboratories |
| Price-to-Book Ratio | 1.23 | 5.37 | Alpa Laboratories |
| Debt-to-Equity Ratio | 0.00 | 3.26 | Alpa Laboratories |
| PEG Ratio | 0.06 | -1.91 | Sun Pharmaceutical |
| EV/EBITDA | 18.60 | 23.66 | Alpa Laboratories |
| Profit Margin (TTM) | 23.77% | 19.29% | Alpa Laboratories |
| Operating Margin (TTM) | -0.68% | 24.34% | Sun Pharmaceutical |
| EBITDA Margin (TTM) | N/A | 24.34% | N/A |
| Return on Equity | 11.38% | 15.08% | Sun Pharmaceutical |
| Return on Assets (TTM) | 8.76% | 11.87% | Sun Pharmaceutical |
| Free Cash Flow (TTM) | $-43.22M | $119.44B | Sun Pharmaceutical |
| Dividend Yield | N/A | 1.26% | N/A |
| 1-Year Return | -16.45% | -13.16% | Sun Pharmaceutical |
| Price-to-Sales Ratio (TTM) | 1.81 | 7.21 | Alpa Laboratories |
| Enterprise Value | $873.67M | $3,629.20B | Sun Pharmaceutical |
| EV/Revenue Ratio | 0.79 | 6.75 | Alpa Laboratories |
| Gross Profit Margin (TTM) | 33.62% | 79.58% | Sun Pharmaceutical |
| Revenue per Share (TTM) | $53 | $224 | Sun Pharmaceutical |
| Earnings per Share (Diluted) | $12.51 | $43.32 | Sun Pharmaceutical |
| Beta (Stock Volatility) | 0.62 | 0.31 | Sun Pharmaceutical |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Alpa Laboratories vs Sun Pharmaceutical Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Alpa Laboratories | -0.06% | -0.22% | -4.30% | -5.42% | -8.01% | -24.08% |
| Sun Pharmaceutical | 1.75% | 1.68% | -0.77% | -1.82% | -4.93% | -14.27% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Alpa Laboratories | -16.45% | 50.06% | 241.99% | 300.81% | 491.79% | 84.00% |
| Sun Pharmaceutical | -13.16% | 75.90% | 230.89% | 81.66% | 743.33% | 2,614.81% |
News Based Sentiment: Alpa Laboratories vs Sun Pharmaceutical
Alpa Laboratories
News based Sentiment: MIXED
Alpa Laboratories experienced a month of conflicting signals: strong profit growth alongside declining revenues, a significant premium to intrinsic value, and a 'Strong Sell' recommendation. These factors create a mixed investment narrative, making September a pivotal month for assessing the company's future prospects.
Sun Pharmaceutical
News based Sentiment: MIXED
September presented a mixed bag for Sun Pharma, with the USFDA's OAI designation for the Halol facility creating immediate concerns, but these were partially offset by the company's reduced reliance on the facility, strong domestic growth, and positive analyst outlook. The month highlights both challenges and opportunities for investors.
Performance & Financial Health Analysis: Alpa Laboratories vs Sun Pharmaceutical
| Metric | ALPA | SUNPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹2.01B | ₹3.94T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 11,339 | 1,807,670 |
| 90 Day Avg. Volume | 15,769 | 2,390,005 |
| Last Close | ₹94.33 | ₹1,648.60 |
| 52 Week Range | ₹90.36 - ₹144.50 | ₹1,553.05 - ₹1,960.35 |
| % from 52W High | -34.72% | -15.90% |
| All-Time High | ₹144.50 (Sep 30, 2024) | ₹1,960.35 (Sep 30, 2024) |
| % from All-Time High | -34.72% | -15.90% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.11% | 0.10% |
| Quarterly Earnings Growth | 1.31% | -0.20% |
| Financial Health | ||
| Profit Margin (TTM) | 0.24% | 0.19% |
| Operating Margin (TTM) | -0.01% | 0.24% |
| Return on Equity (TTM) | 0.11% | 0.15% |
| Debt to Equity (MRQ) | 0.00 | 3.26 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹76.66 | ₹300.99 |
| Cash per Share (MRQ) | ₹53.53 | ₹108.88 |
| Operating Cash Flow (TTM) | ₹11.72M | ₹110.84B |
| Levered Free Cash Flow (TTM) | ₹195.03M | ₹109.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.26% |
| Last 12-Month Dividend | N/A | ₹21.00 |
Valuation & Enterprise Metrics Analysis: Alpa Laboratories vs Sun Pharmaceutical
| Metric | ALPA | SUNPHARMA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 7.55 | 37.28 |
| Forward P/E | 17.87 | 49.42 |
| PEG Ratio | 0.06 | -1.91 |
| Price to Sales (TTM) | 1.81 | 7.21 |
| Price to Book (MRQ) | 1.23 | 5.37 |
| Market Capitalization | ||
| Market Capitalization | ₹2.01B | ₹3.94T |
| Enterprise Value | ₹873.67M | ₹3.63T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.79 | 6.75 |
| Enterprise to EBITDA | 18.60 | 23.66 |
| Risk & Other Metrics | ||
| Beta | 0.62 | 0.31 |
| Book Value per Share (MRQ) | ₹76.66 | ₹300.99 |
Financial Statements Comparison: Alpa Laboratories vs Sun Pharmaceutical
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ALPA | SUNPHARMA |
|---|---|---|
| Revenue/Sales | ₹191.11M | ₹137.86B |
| Cost of Goods Sold | ₹126.87M | ₹28.15B |
| Gross Profit | ₹64.24M | ₹109.71B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-1.29M | ₹33.72B |
| EBITDA | ₹123.69M | ₹47.66B |
| Pre-Tax Income | ₹117.68M | ₹31.73B |
| Income Tax | ₹0 | ₹8.70B |
| Net Income (Profit) | ₹117.68M | ₹22.93B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ALPA | SUNPHARMA |
|---|---|---|
| Cash & Equivalents | ₹265,000 | ₹102.69B |
| Total Current Assets | ₹1.91B | ₹526.24B |
| Total Current Liabilities | ₹466.66M | ₹181.94B |
| Long-Term Debt | ₹0 | ₹3.58B |
| Total Shareholders Equity | ₹1.71B | ₹724.86B |
| Retained Earnings | N/A | ₹578.62B |
| Property, Plant & Equipment | ₹206.04M | ₹100.36B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ALPA | SUNPHARMA |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ALPA | SUNPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 11,339 | 1,807,670 |
| Average Daily Volume (90 Day) | 15,769 | 2,390,005 |
| Shares Outstanding | 21.04M | 2.40B |
| Float Shares | 8.04M | 1.04B |
| % Held by Insiders | 0.57% | 0.56% |
| % Held by Institutions | 0.00% | 0.25% |
Dividend Analysis & Yield Comparison: Alpa Laboratories vs Sun Pharmaceutical
| Metric | ALPA | SUNPHARMA |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹21.00 |
| Last 12-Month Dividend Yield | N/A | 1.26% |
| 3-Year Avg Annual Dividend | N/A | ₹14.67 |
| 3-Year Avg Dividend Yield | N/A | 0.46% |
| 3-Year Total Dividends | N/A | ₹44.00 |
| Ex-Dividend Date | N/A | Jul 07, 2025 |